By Turna Ray

This article was posted May 27.

Genentech recently submitted a supplemental biologics license application with the US Food and Drug Administration for Herceptin (trastuzumab) in addition to chemotherapy as a treatment for HER2-positive stomach cancer, including cancer that affects the gastroesophageal junction.

If approved by the FDA, Herceptin stands to be the first personalized cancer treatment for stomach cancer patients who overexpress the HER2 protein.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.